RES-Q (Registry of Stroke Care Quality) Protocol
- v1.10 -

Table of Contents

RES-Q
Registry of Stroke Care Quality

Objectives and Specific Aims

The objective of this project is the development of an international registry focused on quality of care in stroke treatment with the purpose of:

1. **Providing insight into the current level of stroke treatment delivery as evaluated according to a standardized set of internationally accepted metrics.** This data is intended to serve as a baseline measurement for future implementation initiatives.
2. **Identification of gaps in stroke care delivery.** Benchmarking across varying geographic, political, and socio-economic boundaries will provide information regarding impediments to implementing best-practice interventions.
3. **Providing an evidence base for the development of new stroke care implementation initiatives.** This includes the introduction of governmental healthcare policy recommendations at both national and international levels.
4. **Evaluating the impact of stroke care interventions.** These will be interventions external to the RES-Q protocol, as RES-Q is non-interventional and is only intended to collect, analyze, and evaluate information collected as part of routine clinical practice.

Background and Significance

Effective interventions in stroke care which substantially improve patient outcomes are currently well understood. Guidelines regarding standards of care in stroke treatment are issued and updated regularly from several international professional organizations, with these guidelines being generally consistent across organizations. However, the translation of these guidelines into routine clinical practice is often sub-optimal.

Preliminary data and self-reporting also suggest that there is significant variation in treatment delivery both within and between countries, however there is a lack of data to identify specific gaps, or to provide standardized benchmarks for quality of care. Information collected in RES-Q will allow for retrospective analysis to evaluate existing stroke care quality and provide an evidence base for future interventions.

RES-Q was initially developed as a project of ESO EAST (European Stroke Organization Enhancing and Accelerating Stroke Treatment) to provide an accessible, free to use platform for quality monitoring. The ESO EAST group comprised 23 countries from primarily Eastern Europe and Central Asia. Participation in RES-Q is voluntary, and no remuneration is provided.

Research Methodology

Participation in RES-Q is limited to submission of patient treatment information to the registry, and subsequent use of this information for retrospective research studies targeted at improving the quality of stroke care, and improvements in patient outcomes. The only selection criteria for hospital participation in RES-Q is that the hospital admits stroke patients, or patients suspected of having a stroke.

IRENE
Network for stroke care improvement

cost
EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY
COST is supported by the Framework Programme Horizon 2020

ESO
EUROPEAN STROKE ORGANISATION

1. **Patient data submitted to the registry will be stored electronically and will follow a strict policy of data minimization.** The only potentially identifiable metrics collected are currently limited to age and sex in order to provide basic demographic information. No other identifiable information will be collected in the registry, and all patients will be assigned a generated identification number specific only to RES-Q.
    a. Only patients diagnosed with stroke or admitted with suspicion of stroke should have their data entered in the registry. This includes patients evaluated and/or treated for ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, cerebral venous thrombosis, or clinically defined transient ischemic attack (TIA).
    b. Patients must be entered for at least one month per year, or for a minimum of 30 consecutive patients, whichever is greater. Patients entered to the registry must be consecutive by admission date and must not be selected based on any other criteria beyond those specified in point a. above. Patients may be entered in excess of the minimal requirements; however, they must be entered consecutively based on a predefined time period, in order to minimize selection bias.
2. **The Principal Investigator of RES-Q and the RES-Q management group must approve all retrospective research projects which will involve the use of medical information entered in the registry.** This approval must be obtained prior to access to the registry data being granted and will be assessed based on scientific quality and validity. Evidence of research ethics committee approval must also be provided with any request. All access to medical data in the registry will be documented.
    a. Stored data will only be accessible by the managing RES-Q researchers, users from the site which originally submitted the data, external parties specifically authorized by the submitting sites, and researchers approved by the RES-Q management group.
    b. Data is expected to be stored in perpetuity, or until such time as it is no longer deemed to be valuable to the stated purpose of improving the quality of stroke care.
3. **Patients whose data has been submitted to RES-Q will not be contacted, nor will they be notified of the results of research conducted based on their medical information.**
    a. Informed consent from patients from the European Union whose medical data is entered to RES-Q is not required pursuant to Regulation (EU) 2016/679 General Data Protection Regulation (GDPR). Data collected in RES-Q is collected on the legal bases of legitimate interest and public interest, as specified in Article 6.1(e&f) and Article 9.2(h,i, &j)
    b. Hospitals contributing data from outside the European Union are expected to comply with their own regional and national laws and regulations regarding patient privacy and data protection.

Statistical Considerations and Reporting

As RES-Q is not hypothesis driven, no formal prospective calculations of sample size have been conducted or provided here. However, we will conduct periodic assessments of data validity based on known population sizes, expected incidence rates, and external reporting of stroke quality of care.

The RES-Q management group will generate regular reports of aggregated data at a site level, national level, and international level. These reports will include site specific aggregate results along with national and international benchmarks for all collected metrics. The calculations used in deriving the aggregated results will be part of a statistical analysis plan (SAP) developed by the RES-Q management group and can be requested by participating hospitals at any time.

Aggregate statistical analyses generated as part of the regular reporting are done in accordance with the research methodology described above. Hospitals which do not meet the required minimum participation of 1 month or 30 consecutive patients (whichever is greater), will be excluded from the analysis for the specified time period.

Human Subjects

As participation in the registry does not represent any physical risk to the patient, there is no exclusion criteria specifically related to risk. The racial, gender, and ethnic characteristics of patients entered in the registry will represent the demographics of patients seeking stroke treatment, as patients entered to the registry should be consecutive according to admission date with no other selection criteria. No patients shall be excluded based on race, ethnicity, or gender.

Potential Risks

There are no physical risks to patients based on participation in RES-Q. There is potential risk of breach of data confidentiality and associated patient privacy. These risks will be minimized by:

1. Strict data minimization; only age and gender are collected as demographic information.
2. A unique identifier is assigned to patients in RES-Q, no linkage key is kept unless the contributing site wishes to maintain their own separate key at their own location.
3. All access to the registry and any modification of data is logged, and access is limited by user role.
4. Access to the registry for researchers or external parties must be approved and routinely reviewed by the Principal Investigator for RES-Q.
5. The registry and associated research database are physically housed within the secure hospital infrastructure of St. Anne's University Hospital Brno, in Brno, Czech Republic.

Potential Benefits

There are no direct benefits to patients enrolled in RES-Q. RES-Q is focused on improving the delivery of evidence-based stroke treatments globally, and so any derived benefit will be related to an overall improvement in the quality of stroke care. Retrospective analysis of medical treatment information in RES-Q is intended to guide the development of public health policy and research based on this data is undertaken in the public interest.

RES-Q
Registry of Stroke Care Quality

Costs and Payments

All costs associated with operating and maintaining the registry will be the responsibility of the RES-Q management group with support from the European Stroke Organization. There is no required financial contribution from participating hospitals or health regions, and no cost will be incurred by participants or their healthcare providers. Patients and participating hospitals will not be remunerated for their participation in RES-Q.

Appendix A – RES-Q Questionnaire (v2.0 – Updated Mar.23rd, 2018)

RES-Q Data Collection Form – 2017 update

ADD PATIENT

Study Subject ID:	##################
Enrollment Date:	DD-MM-YYYY
Study:	QR-ESO-EAST

ADMISSION DETAILS

Age: ____ years

Gender: ☐ Male ☐ Female

Last seen normal date: DD-MM-YYYY

Last seen normal time: HH:MM

Date of admission to the first hospital: DD-MM-YYYY

Time of admission to the first hospital: HH:MM

Stroke in the hospital: ☐ Yes ☐ No ☐ Not known

Recurrent stroke: ☐ Yes ☐ No ☐ Not known

HOSPITALIZATION DETAILS

Department type:
- ☐ neurology
- ☐ neurosurgery
- ☐ anesthesiology/resuscitation/critical care department
- ☐ internal medicine
- ☐ geriatrics
- ☐ other

The patient was hospitalized in:
- ☐ Stroke unit / ICU
- ☐ Other monitored

The patient was assessed for rehabilitation needs by PT/OT/ST within the first 72 hours after the admission to the hospital: ☐ Yes ☐ No ☐ Not known

IRENE
Network for stroke care improvement

cost
EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY
COST is supported by the Framework Programme Horizon 2020

ESO
EUROPEAN STROKE ORGANISATION

bed
(telemetry)
☐ Standard bed

Stroke unit: A patient is hospitalized in a stroke unit, if they are admitted in a specialized bed where the patient is monitored, at minimum, for blood pressure, heart rate, oxygen saturation, and EKG.

Stroke type:
☐ Ischemic stroke
☐ Intracerebral hemorrhage
☐ Transient ischemic attack - TIA
☐ Subarachnoid hemorrhage
☐ Venous thrombosis
☐ Undetermined

Stroke type: Add patients diagnosed under the following codes:

- I60 Subarachnoid haemorrhage;
- I61 Intracerebral haemorrhage;
- I62 Other nontraumatic intracranial haemorrhage;
- I63 Cerebral infarction;
- I64 Stroke, not specified as haemorrhage or infarction;
- I67.7 Cerebral arteritis, not elsewhere classified;
- G08 Intracranial and intraspinal phlebitis and thrombophlebitis;
- G45 Transient cerebral ischaemic attacks and related syndromes.

STROKE TYPE: ISCHEMIC STROKE

Level of consciousness on admission:
☐ Alert
☐ Drowsy
☐ Comatose
☐ Glasgow coma scale (GCS)
☐ Unknown

Glasgow coma scale (GCS):
☐ 15 - 13
☐ 12 - 8
☐ < 8

NIHSS on admission:
☐ Not performed
☐ Performed
☐ Not known

Score: ☐

Head CT / MRI:
☐ Not performed
☐ Performed
☐ Not known

Time performed:
☐ Within 1 hour after admission
☐ Later than 1 hour after admission

Was patient put on a ventilator?
☐ Yes
☐ No
☐ Not known

Recanalization procedures:
☐ Not done – primary centre / comprehensive centre
☐ IV tPa – primary centre / comprehensive centre
☐ IV tPa + endovascular treatment – comprehensive centre
☐ Endovascular treatment alone – comprehensive centre
☐ IV tPa + referred to another centre for endovascular treatment – primary centre

- ☐ Referred to another centre for endovascular treatment – primary centre
- ☐ Patient referred to another centre for endovascular treatment and hospitalization continues at the referred to centre – comprehensive centre
- ☐ Patient referred for endovascular treatment and patient is returned to the initial centre – primary centre
- ☐ Patient was returned to the initial centre after recanalization procedures were performed at another centre

RECANALIZATION PROCEDURES: IV tPa (door to needle or bolus time)

Door to needle time:	minutes	Admission time:	HH:MM
		Bolus time:	HH:MM

RECANALIZATION PROCEDURES: IV tPa + endovascular treatment (door to needle or bolus time)

Door to needle time:	minutes	Admission time:	HH:MM
Door to groin puncture time:	minutes	Bolus time:	HH:MM
		Groin puncture time:	HH:MM

RECANALIZATION PROCEDURES: Endovascular treatment alone

Door to groin puncture time:	minutes	Admission time:	HH:MM
		Groin puncture time:	HH:MM

RECANALIZATION PROCEDURES: IV tPa + referred to another center for endovascular treatment (door to needle or bolus time)

Door to needle time:	minutes	Admission time:	HH:MM
Door in - door out time:	minutes	Bolus time:	HH:MM
		Discharge time:	HH:MM

RECANALIZATION PROCEDURES: Referred to another centre for endovascular treatment – primary centre

Door in - door out time:	minutes	Admission time:	HH:MM
		Discharge time:	HH:MM

RECANALIZATION PROCEDURES: Patient referred to another centre for endovascular treatment and hospitalization continues at the referred to centre – comprehensive centre

Door in - door out time:	minutes	Admission time:	HH:MM
		Discharge time:	HH:MM

RECANALIZATION PROCEDURES: Patient referred for endovascular treatment and patient is returned to the initial centre – primary centre

	minutes	Admission time:	HH:MM

RES.Q
Registry of Stroke Care Quality

Door in - door out time: _____

Discharge time: HH:MM

END OF RECANALIZATION PROCEDURES

Dysphagia screening:
- ☐ Yes, Guss test
- ☐ Yes, other
- ☐ Was performed at another centre
- ☐ No
- ☐ Patient could not be tested (intubated)
- ☐ Not known

Time performed:
- ☐ within the first 24 hours after admission to the hospital
- ☐ after the first 24 hours after admission to the hospital

Atrial fibrillation / flutter:
- ☐ Known aFib
- ☐ Newly-detected at admission
- ☐ Detected during hospitalization
- ☐ Not detected
- ☐ Not known

Method of detection:
- ☐ Telemetry with monitor allowing automatic detection of aFib
- ☐ Telemetry without monitor allowing automatic detection of aFib
- ☐ Holter-type monitoring
- ☐ EKG monitoring in an ICU bed with automatic detection of aFib
- ☐ EKG monitoring in an ICU bed without automatic detection of aFib

Was ambulatory heart rhythm monitoring recommended?
- ☐ Yes
- ☐ No

Carotid arteries imaging within 7 calendar days after admission to the hospital:
- ☐ Yes
- ☐ No
- ☐ Not known

Was decompressive craniectomy performed?
- ☐ Yes
- ☐ No
- ☐ Referred to another centre

Which antithrombotic medication was prescribed on discharge?
- ☐ antiplatelets
- ☐ Vitamin K Antagonist
- ☐ dabigatran
- ☐ rivaroxaban
- ☐ apixaban
- ☐ edoxaban
- ☐ LMWH or heparin in prophylactic dose
- ☐ LMWH or heparin in full anticoagulant dose
- ☐ Not prescribed, but recommended
- ☐ nothing

Was the patient discharged on a statin?
- ☐ Yes
- ☐ No

IRENE
Network for stroke care improvement

cost
EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY
COST is supported by the Framework Programme Horizon 2020

ESO
EUROPEAN STROKE ORGANISATION

RES.Q
Registry of Stroke Care Quality

☐ Not known

Was antihypertensive medication prescribed on discharge?
☐ Yes
☐ No
☐ Not known

Symptomatic carotid stenosis:
☐ 50% - 70%
☐ > 70%
☐ No
☐ Not known

Was carotid endarterectomy or angioplasty/stenting done within first two weeks after the stroke onset?
☐ Yes
☐ No
☐ No, but planned later
☐ Referred to another centre

STROKE TYPE: INTRACEREBRAL HEMORRHAGE

- Level of consciousness on admission
- NIHSS on admission
- Head CT / MRI
- Dysphagia screening

Vascular imaging:
☐ CTA
☐ MRA
☐ DSA
☐ None

Was the patient placed on a ventilator?
☐ Yes
☐ No
☐ Not known

Was neurosurgery performed?
☐ Yes
☐ No
☐ Not known

If neurosurgery was performed, select the type:
☐ Intracranial hematoma evacuation
☐ External ventricular drainage
☐ Decompresive craniectomy
☐ Referred to another centre

The reason for bleeding was:
☐ arterial hypertension
☐ aneurysm
☐ arterio-venous malformation
☐ anticoagulation therapy
☐ amyloid angiopathy
☐ Other / not known

STROKE TYPE: TIA

- Head CT / MRI
- Atrial fibrillation / flutter
- Carotid arteries imaging
- Antithrombotic medication
- Discharged on a statin
- Endarterectomy or angioplasty for carotid stenosis

RES.Q
Registry of Stroke Care Quality

STROKE TYPE: SUBARRACHNOID HEMORRHAGE

- Level of consciousness on admission
- Vascular imaging

The reason for bleeding was known:
- ☐ Yes
- ☐ No

Intervention:
- ☐ Endovascular (coiling)
- ☐ Neurosurgical (clipping)
- ☐ Other neurosurgical treatment (decompression, drainage)
- ☐ Patient referred to another hospital for intervention
- ☐ No intervention

STROKE TYPE: VENOUS THROMBOSIS

- Level of consciousness on admission
- NIHSS on admission
- Head CT / MRI
- Ventilator
- Dysphagia screening
- Antithrombotic treatment

Treatment:
- ☐ Anticoagulation
- ☐ Endovascular intervention - thrombectomy
- ☐ Endovascular intervention – local thrombolysis
- ☐ Neurosurgical treatment (decompressive craniectomy)

DISCHARGE

If the patient is a smoker, was he recommended to a smoking cessation program?
- ☐ Yes
- ☐ No
- ☐ Not a smoker

Was the patient recommended to see a cerebrovascular expert?
- ☐ Recommended, and appointment was made
- ☐ Recommended, but the appointment was not made
- ☐ Not recommended

Was antihypertensive medication prescribed at discharge?
- ☐ Yes
- ☐ No
- ☐ Not known

Discharge destination:
- ☐ Home
- ☐ Transferred within the same centre
- ☐ Transferred to another centre
- ☐ Social care facility
- ☐ Dead

Department transferred to within the same centre:
- ☐ Acute
- ☐ rehabilitation

Type of centre transferred to:
- ☐ Stroke centre
- ☐ Comprehensive stroke centre

IRENE
Network for stroke care improvement

cost
EUROPEAN COOPERATION IN SCIENCE AND TECHNOLOGY
COST is supported by the Framework Programme Horizon 2020

ESO
EUROPEAN STROKE ORGANISATION

☐ Another hospital

☐ Long-term care bed
☐ Another department

Type of department transferred to within another centre:
☐ Acute rehabilitation
☐ Long-term care bed
☐ Neurology
☐ Another department

Functional status (mRS) on discharge (see notes at the end of the document).

Date of discharge: DD-MM-YYYY

FUNCTIONAL STATUS (MRS) ON DISCHARGE

0	No symptoms at all
1	No significant disability despite symptoms; able to carry out all usual duties and activities
2	Slight disability, unable to carry out all previous activities, but able to look after own affairs without assistance
3	Moderate disability; requiring some help, but able to walk without assistance
4	Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
5	Severe disability; bedridden, incontinent and requiring constant nursing care and attention

If mRs is UNKNOWN derive from following algorithm (questions a to e):

a) Can the patient walk on their own?
☐ If No go to question **b**
☐ If Yes go to question **c**

b) If the patient can't walk on their own can they walk if someone is helping them?
☐ If Yes score 4
☐ If No score 5

c) If the patient can walk on their own (includes walking aids) do they need help with simple personal activities (toilet, bathing, dressing, cooking, household tasks, simple finances)?
☐ If Yes score 3
☐ If No go to question **d**

d) If they can perform simple personal activities does he need help with more complex usual activities (driving, golf, finances, household bills, work tasks?
☐ If Yes score 2
☐ If No go to question **e**

RES.Q
Registry of Stroke Care Quality

e) If they have no disability do they have any symptoms?

	If Yes score 1
	If No score 0